Almost exactly six years ago AstraZeneca managed to convince investors to reject a takeover bid from Pfizer – and now the UK pharma is reportedly planning its own mega-merger with Gilead. AZ has ...

The deal, first announced last November, would have resulted in the world's biggest pharma company but was ... everyone has been watching Gilead closely to see how it will try to sustain its ...

“We’ll see how this unfolds.” In response to a Fierce Pharma request for comment, a Gilead spokesperson noted that across the two phase 3 trials that included more than 7,500 ...

Bullish option flow detected in Gilead (GILD) with 14,401 calls trading, 4x expected, and implied vol increasing over 4 points to 27.50%.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Regeneron (REGN – Research Report), with a price target ...

Infinity Pharmaceuticals Inc. 0.00% $90.76 ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...